Results 11 to 20 of about 14,833,612 (178)

Dihydrotanshinone I protects human chondrocytes and alleviates damage from spontaneous osteoarthritis in a guinea pig model. [PDF]

Sci Rep, 2023
Osteoarthritis (OA) is the most common degenerative joint disease. Currently, no satisfactory pharmacological treatment exists for OA. The potential anti-inflammatory properties of Dihydrotanshinone I (DHT) have been reported, but its effects on OA are ...
Zhang YZ, Wei ZJ, Yu SN, Wang XY, Wang Y, Wu CA, Jiang X.   +6 more
europepmc   +5 more sources

Dihydrotanshinone I Specifically Inhibits NLRP3 Inflammasome Activation and Protects Against Septic Shock In Vivo. [PDF]

Front Pharmacol, 2021
The abnormal activation of the NLRP3 inflammasome is closely related to the occurrence and development of many inflammatory diseases. Targeting the NLRP3 inflammasome has been considered an efficient therapy to treat infections.
Wei Z, Zhan X, Ding K, Xu G, Shi W, Ren L, Fang Z, Liu T, Hou X, Zhao J, Li H, Li J, Li Z, Li Q, Lin L, Yang Y, Xiao X, Bai Z, Cao J.   +18 more
europepmc   +6 more sources

Antiproliferative effects of dihydrotanshinone I on autosomal dominant polycystic kidney disease via immunomodulation. [PDF]

J Pharmacol Exp Ther
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder affecting individuals worldwide and is one of the leading causes of end-stage renal disease.
Mahendran R, Lim SK, Ong KC, Chua KH, Chai HC.   +4 more
europepmc   +3 more sources

Engineered endothelial cells targeting and dihydrotanshinone I loaded bacterial extracellular vesicles for atherosclerosis therapy. [PDF]

Bioeng Transl Med
Atherosclerosis (AS) is a complex cardiovascular disease characterized by endothelial dysfunction, dyslipidemia, and immune‐inflammatory responses, leading to arterial plaque formation and potentially fatal complications such as myocardial infarction and
Zhu RR, Zhou XL, Liu YW, Xu R, Deng P, Liu ZY.   +5 more
europepmc   +3 more sources

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells. [PDF]

Molecules, 2022
Oxaliplatin (OXA) is a first-line chemotherapeutic drug for the treatment of colorectal cancer (CRC), but acquired drug resistance becomes the main cause of treatment failure.
Wang M, Xiang Y, Wang R, Zhang L, Zhang H, Chen H, Luan X, Chen L.   +7 more
europepmc   +5 more sources

Enhanced Bioavailability of Dihydrotanshinone I-Bovine Serum Albumin Nanoparticles for Stroke Therapy. [PDF]

Front Pharmacol, 2021
Dihydrotanshinone I (DHT) is a natural component in Salvia miltiorrhiza and has been widely researched for its multiple bioactivities. However, poor solubility and biocompatibility of DHT limit its desirable application for clinical purposes. Herein, DHT was encapsulated with bovine serum albumin (BSA) to enhance bioavailability.
Ren Y, Feng Y, Xu K, Yue S, Yang T, Nie K, Xu M, Xu H, Xiong X, Körte F, Barbeck M, Zhang P, Liu L.   +12 more
europepmc   +5 more sources

Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. [PDF]

Antimicrob Agents Chemother, 2021
Helicobacter pylori is a major global pathogen and has been implicated in gastritis, peptic ulcer, and gastric carcinoma. The efficacy of the extensive therapy of H. pylori infection with antibiotics is compromised by the development of drug resistance and toxicity toward human gut microbiota, which ...
Luo P, Huang Y, Hang X, Tong Q, Zeng L, Jia J, Zhang G, Bi H.   +7 more
europepmc   +4 more sources

Biotransformation of triterpenoid ganoderic acids from exogenous diterpene dihydrotanshinone I in the cultures of Ganoderma sessile. [PDF]

Microb Cell Fact, 2023
Background Triterpenoids have shown a wide range of biological activities including antitumor and antiviral effects. Typically, triterpenes are synthesized through the mevalonate pathway and are extracted from natural plants and fungi.
Wang X, Wu H, Wong KH, Wang Y, Chen B, Feng K.   +5 more
europepmc   +2 more sources

Dihydrotanshinone I inhibits human glioma cell proliferation via the activation of ferroptosis. [PDF]

Oncol Lett, 2020
The aim of the present study was to investigate the effect of dihydrotanshinone I (DHI) on the survival of human glioma cells and the expression levels of ferroptosis-associated proteins. Human U251 and U87 glioma cells were cultured in vitro and treated with different concentrations of DHI and/or the ferroptosis inhibitor ferrostatin-1.
Tan S, Hou X, Mei L.
europepmc   +4 more sources

15,16-Dihydrotanshinone I, a novel β-catenin-targeting inhibitor that inhibits its nuclear translocation and reduces downstream CD36 expression in cancer. [PDF]

J Transl Med
Wnt/β-catenin signaling drives many cancers; however, current inhibition strategies have limitations. Direct β-catenin inhibitors that block nuclear translocation represent an alternative therapeutic approach.
Chen M, Chen B, He Q, Xiao S, Li B, Ye Y, Zhang H, Wong HLX, Ji Y, Su T, Kwan HY.   +10 more
europepmc   +2 more sources